143 Results for "

monoclonal IgG4 antibody

" in MedChemExpress (MCE) Product Catalog:
Products (143)

143 Results for "monoclonal IgG4 antibody" in MCE Product Catalog:

14
14 Publications Verification
Cat. No.: HY-P99003

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology

Human IgG4 (S228P) kappa, Isotype Control, a human-derived monoclonal antibody, is an isotype control for human IgG4κ antibody.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P9971
CAS No.: 1798286-48-2
Synonyms: SHR-1210; INCSHR1210

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-108831A
CAS No.: 189261-10-7
Purity:  98.72%
Synonyms: AN100226; BG00002
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-108831
CAS No.: 189261-10-7
Purity:  99.10%
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99048
CAS No.: 2072873-06-2
Synonyms: IBI308

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99305
CAS No.: 272780-74-2
Synonyms: CAT-192; Anti-TGFB1 Recombinant antibody

Target:  

TGF-β Receptor

Research Areas:  

Inflammation/Immunology

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1 .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P9924
CAS No.: 1143503-69-8
Synonyms: LY2439821

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99631
CAS No.: 2162134-62-3
Synonyms: CSL312

Target:  

Factor Xa

Research Areas:  

Cardiovascular Disease

Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99053
CAS No.: 1044515-88-9
Synonyms: CAT354
Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99008
CAS No.: 2417175-94-9
Synonyms: IC14
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P9979
CAS No.: 1584645-37-3
Synonyms: UCB7665

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99055
CAS No.: 934823-49-1
Synonyms: BMS-663513
Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology Cancer

Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99021
CAS No.: 1578199-75-3
Synonyms: LY 2951742
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99632
CAS No.: 2097125-54-5
Synonyms: REGN 2477

Target:  

TGF-β Receptor

Research Areas:  

Inflammation/Immunology

Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99194
CAS No.: 1446419-85-7
Synonyms: REGN1500

Target:  

ANGPTL

Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99706
CAS No.: 2428381-55-7
Synonyms: AK 117

Research Areas:  

Cancer

Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99673
CAS No.: 2226742-52-3
Synonyms: REGN-3500; SAR-440340

Research Areas:  

Inflammation/Immunology

Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99376
CAS No.: 2108782-45-0
Synonyms: OMS 721; Anti-MASP2 Reference antibody (narsoplimab)

Target:  

SARS-CoV

Research Areas:  

Infection

Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99283
CAS No.: 1312299-39-0
Synonyms: NN 7415; mAb 2021; Anti-TFPI Recombinant antibody

Target:  

Factor Xa

Research Areas:  

Others

Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99263
CAS No.: 1256258-86-2
Synonyms: Anti-Human selectin P Recombinant antibody

Target:  

P-selectin

Research Areas:  

Cardiovascular Disease

Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
loading...
    loading...